The Canadian maker of a rapid COVID-19 test has filed for creditor protection after pausing shipments of the product due to a recently identified issue with the system.
Spartan Bioscience Inc. says the problem is not a safety issue.
The Ottawa-based company says it’s seeking protection from creditors while it restructures its operations and refines the test’s performance.
Spartan says it’s laying off 60 employees, or around 70 per cent of its workforce.
Get weekly health news
Despite the challenges, Spartan says it remains committed to mobile DNA-testing technology in the fight against COVID-19.
It says Health Canada’s authorization remains in place while Spartan works with the agency to resolve the issue.
- ‘Brutal winter’ leaves Toronto roads battered as city launches 3rd pothole blitz
- Former PM Joe Clark’s boyhood home hits the market for less than $1 million
- China denies forced labour allegations amid fallout from Michael Ma’s comments
- Family fighting to bring B.C. senior home after she fell into a coma in China
Interim CEO Jennifer Ross-Carriere said Spartan Bioscience is a Canadian company working to protect the health and safety of all Canadians.
“We believe Canada needs more innovation in the biosciences sector and we are incredibly proud of our team for quickly designing and manufacturing the only made-in-Canada rapid diagnostic PCR COVID-19 test,” Ross-Carriere wrote in an email.
Comments
Want to discuss? Please read our Commenting Policy first.